Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
89bio, Inc.
Age
21–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 21 to 75
Biopsy-confirmed NASH with fibrosis stage F2 or F3 per NASH CRN System and NAS ≥4, with a score of at least 1 in each of steatosis, ballooning degeneration, and lobular inflammation.
* Qualifying biopsy must be either within 6 months of screening visit or obtained during screening period
You may not be if
Have poorly controlled high blood pressure
Have type 1 diabetes or poorly controlled type 2 diabetes.
History of cirrhosis or evidence of cirrhosis by clinical, imaging, or liver biopsy evaluation
Are planning to try to lose weight during the conduct of the study.
Have a BMI \<25 kg/m2
Clareo Health | Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
